Cure My Disease

Don't miss your cure!

Log in / Sign up

← Back to home

Bioverativ, A Sanofi Company

Clinical trials sponsored by Bioverativ, A Sanofi Company, explained in plain language.

Now part of Sanofi S.A. SNY NASDAQ

A biopharmaceutical company focused on therapies for hemophilia and other rare blood disorders.

Trade on eToro (ad)

Not investment advice. Company information is shown for context only. Clinical trials frequently fail.

Not yet finished but already full! 1 Completed 6 Terminated 1

Can a new clotting factor offer better bleed protection for severe hemophilia?

Disease control Ongoing

This phase 3 trial is investigating the long-term safety and effectiveness of an experimental clotting factor called BIVV001 in people with severe hemophilia A. The study aims to see if regular infusions of this therapy can prevent bleeding episodes, protect joint health, and imp…

Phase: PHASE3 • Sponsor: Bioverativ, a Sanofi company • Aim: Disease control

Last updated Jul 30, 2026 00:00 UTC